The FDA approved a next-generation hybrid closed-loop insulin delivery system for children aged 2 to 6 years with type 1 diabetes, according to an agency press release. The MiniMed 770G system (Medtronic) is a hybrid closed-loop diabetes management device intended to automatically monitor glucose and provide appropriate basal insulin doses with little or no input from users or their caregivers. The 770G system is the first legally marketed device that can automatically adjust insulin delivery based on continuous glucose monitor values for a young pediatric population.